BioCentury reported Chinese regulators introduced rules permitting medical centers to charge for investigational gene and cell therapies, a shift that creates incentives for hospitals to deploy new advanced therapies. The guidance adds rigor while unlocking financial pathways to scale novel treatments in China’s hospital network. PitchBook analysis reinforced China’s strength in early‑stage drugmaking, forecasting continued licensing activity and sustained edge in early assets and cell and gene candidates. Together the developments suggest China is aligning regulation, finance, and commercialization to keep momentum in cell and gene therapy development and global partnering.